Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea
· Delayed Price · Currency is KRW 426,000
-4,000 (-0.93%)
At close: Dec 5, 2025
Hanmi Pharm. Revenue
Hanmi Pharm. had revenue of 362.35B KRW in the quarter ending September 30, 2025, with 0.07% growth. This brings the company's revenue in the last twelve months to 1.47T, down -6.39% year-over-year. In the year 2024, Hanmi Pharm. had annual revenue of 1.50T with 0.31% growth.
Revenue (ttm)
1,466.18B
Revenue Growth
-6.39%
P/S Ratio
3.68
Revenue / Employee
610.91M
Employees
2,400
Market Cap
5,401.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,495.50B | 4.61B | 0.31% |
| Dec 31, 2023 | 1,490.89B | 159.34B | 11.97% |
| Dec 31, 2022 | 1,331.55B | 128.36B | 10.67% |
| Dec 31, 2021 | 1,203.19B | 127.33B | 11.84% |
| Dec 31, 2020 | 1,075.85B | -37.80B | -3.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |
Hanmi Pharm. News
- 17 days ago - Aptose Biosciences agrees to be acquired by Hanmi Pharmaceutical subsidiary for C$2.41 per share - Seeking Alpha